Please type a plus sign (+) inside this box → [+]

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0654-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known	
Application Number	09/801,089
Filing Date	March 8, 2001
First Named Inventor	Phillips, David R.
Group Art Unit	1644
Examiner Name	Ewoldt, Gerald R.
Attorney Docket Number	MPI95-015P1RCPA1DV1M

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T[2]
	B1	Valmu, L., et al., "Phosphorylation of the ß-subunit of CD11/CD18 integrins by protein kinase C correlates with leukocyte adhesion", European Journal of Immunology (1991), Volume 21, pages 2857-2862	
	B2	Chatila, T.A., et al., "Constitutive and Stimulus-induced Phosphorylation of CD11/CD18 Leukocyte Adhesion Molecules", The Journal of Cell Biology, (December 1989), Volume 109, pages 3435-3444	

Examiner Signature	Ewoldt 8/25/04	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Unique citation design number. [2]Applicant is to place a check mark here is English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box → [+]

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0654-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known	
Application Number	09/801,089
Filing Date	March 8, 2001
First Named Inventor	Phillips, David R.
Group Art Unit	1644
Examiner Name	Ewoldt, Gerald R.
Attorney Docket Number	MPI95-015P1RCPA1DV1M

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document (MM-DD-YYYY)	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
RE		5192746		Lobl, et al.	March 1993	
		5260277		McKenzie	November 1993	
RE		5580979		Bachovchin	December 1996	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document (MM-DD-YYYY)	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

Examiner Signature	RE 8/25/04	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Unique citation design number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box → [+]

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	6

Complete If Known

Application Number	09/801,089
Filing Date	March 8, 2001
First Named Inventor	Phillips, David R.
Group Art Unit	1644
Examiner Name	Ewoldt, Gerald R.
Attorney Docket Number	MPI95-015P1RCPA100-M

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T[2]
SPE		Mikayama, T., et al. Molecular Cloning and Functional Expression of CDNA Encoding Glycocylation Inhibiting Factor Proceedings of the National Academy of Sciences USA (90) 10056-10060 November 1993.	
		Scarborough, et al., Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa, pp60c-src, pp62c-yes, and the p21ras GTPase-activating protein with the membrane skeleton. Journal of Biological Chemistry 268:1066-1073 (1993).	
		Fox, et al., On the role of the platelet membrane skeleton in mediating signal transduction Association of GP IIb-IIIa, pp60c-src, pp62c-yes, and the p21ras GtPase-activating protein with the membrane skeleton Journal of Biological Chemistry 268:25973-25964 (1993).	
		Dorahy, et al., v Capture by chemical crosslinkers provides evidence that integrin alpha IIb beta 3 forms a complex with protein tyrosine kinases in intact platelets. Biochemistry Journal 309: 481-490 (1995).	
		Argraves, W.S., et al., Fibulin, a novel protein that interacts with the fibronectin receptor beta subunit cytoplasmic domain. Cell 58:623-629 (1989).	
		Bartfield, N.S., et al., The alpha v beta 3 integrin associates with a 190-kDa protein that is phosphorylated on tyrosine in response to platelet-derived growth factor. Journal of Biological Chemistry 268:17270-17276 (1993).	
		Chen, Y.P., et al., Ser-752-->Pro mutation in the cytoplasmic domain of integrin beta 3 subunit and defective activation of platelet integrin alpha IIb beta 3 (glycoprotein IIb-IIIa) in a variant of Glanzmann thrombasthenia. Proceedings of the National Academy of Sciences USA 89:10169-10173 (1992).	
		Clark, et al., Integrins and signal transduction pathways: the road taken. Science 268:233-239 (1995)	
		Elmore, M. A., et al., Tyrosine-specific phosphorylation of gpIIIa in platelet membranes. FEBS Letters 269:283-287 (1990).	
SPE		Filardo, E.J., et al., Requirement of the NPXY motif in the integrin beta 3 subunit cytoplasmic tail for melanoma cell migration in vitro and in vivo. Journal of Cell Biology 130:441-450(1995).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Unique citation design number. [2]Applicant is to place a check mark here is English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box → [+]

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	2	of	6

Complete if Known	
Application Number	09/801,089
Filing Date	March 8, 2001
First Named Inventor	Phillips, David R.
Group Art Unit	1644
Examiner Name	Ewoldt, Gerald R.
Attorney Docket Number	MPI95-015P1RCPA1DV1M

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T[2]
DRE		Findik, D., et al., Platelet membrane glycoproteins IIb and III a are substrates of purified pp60c-src protein tyrosine kinase. FEBS Letters 262:1-4 (1990).	
		Fitzgerald, L., et al., Protein sequence of endothelial glycoprotein IIIa derived from a cDNA clone. Identity with platelet glycoprotein IIIa and similarity to "integrin". Journal of Biological Chemistry 262-3936-3939 (1987).	
		Ginsberg, M.H., et al., Inside-out integrin signaling. Current Opinion in Cell Biology 4:766-771 (1992).	
		Ginsberg, M.H., et al., Platelet integrins. Thrombosis and Haemostasis 70:87-93 (1993).	
		Ginsberg, M.H., et al., Dynamic regulation of integrins. Stem Cells, 13:38-46 (1995).	
		Grinblat, Y., et al., Functions of the cytoplasmic domain of the beta PS integrin subunit during Drosophila development. Development 120:91-102 (1994).	
		Hannigan, G.E., et al., Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase. Nature 379:91-96 (1996).	
		Hayashi, Y., et al. Expression and function of chicken integrin beta 1 subunit and its cytoplasmic domain mutants in mouse NIH 3T3 cells. Journal of Cell Biology 110:175-184 (190).	
DRE		Hibbs, M.L., et al., The cytoplasmic domain of the integrin lymphocyte function-associated antigen 1 beta subunit: sites required for binding to intercellular adhesion molecule 1 and the phorbol ester-stimulated phosphorylation site. Journal of Experimental Medicine 174:1227-1238 (1991).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Unique citation design number. [2]Applicant is to place a check mark here is English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box → [+]

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0654-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 6

Complete if Known	
Application Number	09/801,089
Filing Date	March 8, 2001
First Named Inventor	Phillips, David R.
Group Art Unit	1644
Examiner Name	Ewoldt, Gerald R.
Attorney Docket Number	MPI95-015P1RCPA1DV1M

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T[2]
		Hillary, C.A., et al., Phosphorylation of human platelet glycoprotein IIIa (GPIIIa). Disociation from fibrinogen receptor activation and phosphorylation of GPIIIa in vitro. Journal of Biological Chemistry 266:14663-14669 (1991).	
		Hirst, R., et al., Phosphorylation of the fibronectin receptor complex in cells transformed by oncogenes that encode tyrosine kinases. Proceedings of the National Academy of Sciences USA 83:6470-6474 (1986).	
		Horwitz, A., et al.,Interaction of plasma membrane fibronectin receptor with talin—a transmembrane linkage. Nature 320:531-533 (1986).	
		Huang, M-M., et al., Adhesive ligand binding to integrin alpha IIb beta 3 stimulates tyrosine phosphorylation of novel protein substrates before phosphorylation of pp125FAK. Journal of Cell Biology 122:473-483 (1993).	
		Hughes, P.E., et al., The conserved membrane-proximal region of an integrin cytoplasmic domain specifies ligand binding affinity. Journal of Biological Chemistry 270:12411-12417 (1995).	
		Hynes, R.O., Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69:11-25 (1992).	
		Johansson, M.W., et al., Altered localization and cytoplasmic domain-binding properties of tyrosine-phosphorylated beta 1 integrin. Journal of Cell Biology 126:1299-1309 (1994).	
		Juliano, R.L., et al., Signal transduction from the extracellular matrix. Cell Biology 120:577-585 (1993).	
		Kieffer, N., et al., Adhesive properties of the beta 3 integrins: comparison of GP IIb-IIIa and the vitronectin receptor individually expressed in human melanoma cells. Journal of Cell Biology 113:451-461 (1991).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Unique citation design number. [2]Applicant is to place a check mark here is English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box → [+]

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0654-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 6

Complete if Known	
Application Number	09/801,089
Filing Date	March 8, 2001
First Named Inventor	Phillips, David R.
Group Art Unit	1644
Examiner Name	Ewoldt, G.
Attorney Docket Number	MPI95-015P1RCPA1B/AM

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T[2]
JPE		LaFlamme, S.E., et al., Single subunit chimeric integrins as mimics and inhibitors of endogenous integrin functions in receptor localization, cell spreading and migration, and matrix assembly. Journal of Cell Biology 126:1287-1298 (1994).	
		Lanza, F., et al., cDNA cloning and expression of platelet p24/CD9. Evidence for a new family of multiple membrane-spanning proteins. Journal of Biological Chemistry. 266:10638-10645 (1991)	
		Luscinskas, et al. Integrins as dynamic regulators of vascular function. The FASEB Journal 8:929-938 (1994).	
		O'Toole, T.E., et al., Affinity modulation of the alpha IIb beta 3 integrin (platelet GPIIb-IIIa) is an intrinsic property of the receptor. Cell Regulation 1:883-893 (1990).	
		O'Toole, T.E., Regulation of integrin affinity states through an NPXY motif in the beta subunit cytoplasmic domain. Journal of Biological Chemistry 270:8553-8558 (1995).	
		Otey, C.A., et al., Mapping of the alpha-actinin binding site within the beta 1 integrin cytoplasmic domain. Journal of Biological Chemistry 268:21193-21197 (1993).	
		Parise, L.V., et al., Glycoproten IIIa is phosphorylated in intact human platelets. Blood 75:2363-2368 (1990).	
		Phillips , D.R., et al. The platelet membrane glycoprotein IIb-IIIa complex. Blood 71:831-843 (1988).	
JPE		Phillips, D.R., et al., GPIIb-IIIa: the responsive integrin. Cell 65:359-362 (1991).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Unique citation design number. [2]Applicant is to place a check mark here is English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box → [+]

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 6

Complete if Known	
Application Number	09/801,089
Filing Date	March 8, 2001
First Named Inventor	Phillips, David R.
Group Art Unit	1644
Examiner Name	Ewoldt, Gerald R.
Attorney Docket Number	MPI95-015P1RCPA1DV1M

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T[2]
GEW		Reszka, A.A., Identification of amino acid sequences in the integrin beta 1 cytoplasmic domain implicated in cytoskeletal association. Journal of Cell Biology 117:1321-1330 (1992).	
		Rouslahti, E., Integrins. The Journal of Clinical Investigations 87:1-5 (1991).	
		Schaller, M.D., et al., Focal adhesion kinase and paxillin bind to peptides mimicking beta integrin cytoplasmic domains. Journal of Cell Biology 130:1181-1187 (1995).	
		Shattil, S.J., et al., Thrombosis and Haemostasis 73:1190 (1995).	
		Shattil, S.J., et al., Changes in the platelet membrane glycoprotein IIb.IIIa complex during platelet activication. Journal Biological Chemistry 260:11107-11114 (1985).	
		Smyth, S.S., et al., Regulation of vascular integrins. Blood 81:2827-2843 (1993).	
		Diamond, M.S., The dynamic regulation of integrin adhesiveness. Current Biology 4:506-517 (1994).	
		Tamkun, J.W., et al., Structure of integrin, a glycoprotein involved in the transmembrane linkage between fibronectin and actin. Cell 46:271-282 (1986).	
GEW		Tapley, P., et al., Integrins isolated from Rous sarcoma virus-transformed chicken embryo fibroblasts. Oncogene 4:325-333 (1989).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Unique citation design number. [2]Applicant is to place a check mark here is English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box → [+]

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0654-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 6

Complete if Known

Application Number	09/801,089
Filing Date	March 8, 2001
First Named Inventor	Phillips, David R.
Group Art Unit	1644
Examiner Name	Ewoldt, Gerald R.
Attorney Docket Number	MPI95-015P1RCPA1DV1M

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T[2]
GE		Tcheng, J.E., et al., Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators. Circulation 91:2151-5157 (1995).	
		The EPIC Investigation, New England Journal of Medicine 330:956-961 (1994).	
		Vuori, K., et al., Mutation of the cytoplasmic domain of the integrin beta 3 subunit. Differntial effects on cell spreading, recruitment to adhesion plaques, endocytosis, and phagocytosis. Journal of Biological Chemistry 270:9550-9557 (1995).	
		Ylanne, J., et al., Distinct functions of integrin alpha and beta subunit cytoplasmic domains in cell spreading and formation of focal adhesion. Journal of Cell Biology 122:223-233 (1993).	
		Lanza, Characterization of the human platelet glycoprotein IIIa gene. Comparison with the fibronectin receptor beta-subunit gene. Journal of Biological Chemistry, 265(30):18098-18103 (1990).	
GE		Lukashev, Disruption of integrin function and induction of tyrosine phosphorylation by the autonomously expressed beta 1 integrin cytoplasmic domain. Journal of Biological Chemistry, 269(28):18311-18314 (1994).	

Examiner Signature	GE 8/25/04	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Unique citation design number. [2]Applicant is to place a check mark here is English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.